Drug Injury attorney and Product Liability lawyer investigating PML infection and liver damage injury in MS patients taking Tecfidera


The U.S. Food and Drug Administration (FDA) has warned that patients with multiple sclerosis (MS) being treated with Tecfidera (dimethyl fumarate) may develop a rare and severe brain infection called progressive multifocal leukoencephalopathy (PML). As a result, PML warnings were added to the Tecfidera drug label, listed among other drug injury risks associated with the MS drug.

Biogen has also added other warnings to the multiple sclerosis drug, including potential liver injury that could require hospitalization for prescribed patients. Progressive multifocal leukoencephalopathy (PML) is quite rare, though is potentially fatal, and can be induced by certain drugs used in the treatment of MS, such as natalizumab, fingolimod and dimethyl fumarate. Tecfidera has been implicated in the development of PML.

Joe Lyon is a highly-rated pharmaceutical injury attorney reviewing PML infection and liver damage risks for MS patients taking Tecfidera. The Lyon Firm has experience engaging large drug companies in product liability lawsuits following defective drug injuries.


Tecfidera Injury Risks & PML Infection

Tecfidera (dimethyl fumarate) is a brand-name prescription medication used to treat relapsing forms of multiple sclerosis (MS), a brain and spinal cord disease in which patients experience episodes of weakness, numbness, and other nervous system issues. Biogen has reported that more than 100,000 patients with MS worldwide have taken Tecfidera since the drug was approved in 2013.

Progressive multifocal leukoencephalopathy (PML) is a rare brain infection directly caused by the John Cunningham (JC) virus, a common virus that is harmless in most people without weakened immune systems. Symptoms of PML may include weakness on one side of the body, vision problems, confusion, and changes in personality, memory loss, and disorientation.

Biogen notified the FDA when an MS patient died after developing PML. The patient had taken Tecfidera for more than four years. There are many unknowns about the cause of PML, though medical professionals and patents are urged to take caution with any MS medication.

If you or a loved one has suffered an injury due to a defective drug, and have questions about the root cause and the legal remedies available to improve quality of life and medical care, contact The Lyon Firm at (800) 513-2403. You will speak directly with Mr. Lyon, and he will help you answer these critical questions.